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Take Home message 
Chronic infection with Pseudomonas or other bacteria and daily sputum identify 4 clinical 
phenotypes in bronchiectasis 
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ABSTRACT  
 
Bronchiectasis is a heterogeneous disease. This study aimed at identifying discrete groups of patients 
with different clinical and biological characteristics, and long-term outcomes.  
This was a secondary analysis of five European databases of prospectively enrolled adult outpatients 
with bronchiectasis. Principal component and cluster analysis were performed using demographics, 
comorbidities, clinical, radiological, functional and microbiological variables collected during stable 
state. Exacerbations, hospitalizations and mortality during a 3-year follow-up were recorded. Clusters 
were externally validated in an independent cohort of patients with bronchiectasis, investigating also 
inflammatory markers in sputum. 
Among 1,145 patients (median age: 66 years, 40% males), four clusters were identified driven by the 
evidence of chronic infection with P. aeruginosa or other pathogens and daily sputum: 
“Pseudomonas” (16%), “Other chronic infection” (24%), “Daily sputum” (33%) and “Dry 
bronchiectasis” (27%). Patients in the four clusters showed significant differences in terms of quality 
of life, exacerbations, hospitalizations and mortality during follow up. In the validation cohort, 
neutrophil elastase, myeloperoxidase and interleukin-1β levels in sputum were significantly different 
among the clusters. 
Identification of four clinical phenotypes in bronchiectasis could favour focused treatments and 
interventions in further interventional studies designed to alter the natural history of the disease. 
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INTRODUCTION 
 
Bronchiectasis is a chronic airway disease characterized by irreversibly damaged and dilated airways 
leading to recurrent episodes of bronchial sepsis. This results in poor mucus clearance and a vicious 
cycle of persistent bacterial colonization, airway obstruction, inflammation, and progressive tissue 
destruction [1]. 
The population of patients with bronchiectasis is extremely heterogeneous representing a group of 
disorders with a wide range of causes and varying clinical, radiological and microbiological features 
[2]. There are no licensed therapies for bronchiectasis and limited evidence even for widely used 
treatments such as physiotherapy and long-term macrolide treatment. Recently, a therapeutic 
approach based on the severity of the disease has been suggested [3]. A step towards a more 
individualized management of bronchiectasis patients would be the identification of distinct clinical 
phenotypes using a multidimensional approach that includes parameters available in daily clinical 
practice.  
The majority of therapeutic approaches in bronchiectasis is aimed at the management of chronic 
bacterial infections, with short and long-term antibiotic courses [3]. It is not known, however, if those 
patients with chronic bacterial colonization or colonization with Pseudomonas aeruginosa present 
different clinical characteristics to those patients without. The clinical heterogeneity that characterizes 
patients with bronchiectasis might reflect different patho-physiological mechanisms, which could be 
considered potential targets for therapeutic interventions. Cluster analysis or unsupervised machine 
learning techniques have been successfully used to identify biological and clinical subgroups or 
“phenotypes” in other respiratory disorders such as asthma and COPD [4]. 
In light of the heterogeneity that characterizes patients with bronchiectasis and the need for better 
directing current management and targeting future treatments, we hypothesized that among these 
patients there would be discrete groups of subjects with different clinical and biological 
characteristics.  
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MATERIALS AND METHODS 
 
Study population 
This was a secondary analysis of five databases of prospectively enrolled outpatients with 
bronchiectasis referred to the bronchiectasis clinics of university teaching hospitals in Monza (Italy), 
Dundee (UK), Leuven (Belgium), Athens (Greece) and Galway (Ireland). Consecutive patients aged 
≥18 years with a diagnosis of bronchiectasis on high-resolution computed tomography (HRCT) scan 
in stable state were enrolled. Patients with cystic fibrosis or traction bronchiectasis due to pulmonary 
fibrosis were excluded. A further exclusion criterion for the Athens cohort was either admission to 
the hospital or use of antibiotics in the prior four weeks and for the Leuven cohort was the presence 
of active cancer. Collection of selected variables was approved at each individual center by the local 
ethical committee or institutional review board. 
 
Data collection 
At the time of clinical assessment, all patients underwent the same comprehensive diagnostic work-
up in each site as suggested by the 2010 British Thoracic Society (BTS) guidelines [1]. 
Demographics, comorbidities, disease severity, etiology of bronchiectasis, respiratory symptoms, 
sputum evaluation, radiological, functional and laboratory findings on stable state, quality of life, 
long-term treatments and outcomes (including exacerbations, hospitalizations and mortality) during 
a three-year follow-up were uniformly recorded in each database. 
The Charlson comorbidity index was used to assess comorbidities; this is a sum score of 19 weighted 
diseases with higher scores denoting increasing burden of comorbidities [5]. The severity of 
bronchiectasis was evaluated according to both the Bronchiectasis Severity Index (BSI) and FACED 
score (evaluating FEV1, Age, Ahronic infection with Pseudomonas, radiological Extension and 
Dyspnea)  [6,7]. Radiological severity of bronchiectasis was assessed using a modified Reiff score, 
which rates the number of involved lobes (with the lingula considered to be a separate lobe) and the 
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degree of dilatation (range: 1-18) [8]. Patients completed the St. George’s Respiratory Questionnaire 
(SGRQ) as a measure of quality of life [9]. All bacteriology was performed on spontaneous sputum 
samples as previously described [10]. Murray-Washington criteria for sputum quality was used in all 
cases, with all samples having less than 10 squamous cells and more than 25 leukocytes per low-
power microscope field. Chronic infection was defined by the isolation of potentially pathogenic 
bacteria in sputum culture on two or more occasions, at least 3 months apart over a 1-year period 
[11]. The predominant pathogen was the organism grown most frequently over the study period. 
Patients who were unable to provide sputum samples due to absence of a productive cough were 
classified as not having chronic infection for the purposes of analysis. 
 
Study outcomes 
Exacerbations. An exacerbation of bronchiectasis was defined as a clinical diagnosis of exacerbation 
for which antibiotics were prescribed in the presence of at least one (and usually more than one) of 
the following symptoms: increasing cough, increasing sputum volume, worsening sputum purulence, 
worsening dyspnea, increased fatigue/malaise, fever, and haemoptysis [1]. Hospitalization for severe 
exacerbations. Severe exacerbations were defined according to the BTS guidelines, and unscheduled 
hospitalizations or emergency department visits for severe bronchiectasis exacerbations or 
complications were recorded from patient histories and verified using an administrative database that 
records all regional hospital admissions [1]. Mortality. All-cause mortality for up to 3 years was 
evaluated.  
 
Statistical analysis  
An electronic form was used to collect epidemiological, demographic, clinical, and follow-up 
variables in the clinical centers participating in the project. Qualitative and quantitative variables were 
summarized using relative frequencies (percentages) and medians (interquartile ranges, IQR), when 
appropriate. A chi-squared test and Kruskall-Wallis test were performed to evaluate qualitative and 
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quantitative variables, respectively. A p-value of <0.05 was used to consider a difference statistically 
significant. A Spearman correlation analysis was performed between all the collected variables; a rho 
>0.3 was used to select variables to be included in the principal component analysis (PCA). A cut-
off eigenvalue of 0.7 was adopted to choose the components, and a factor loading of 0.4 was 
considered to identify the most important variables to be selected in the cluster analysis [12]. After 
hierarchical analysis a dendrogram was prepared to visually assess the distribution of the clusters 
related to the recruited cohort. The number of clusters was decided on the basis of a 20 Gower 
dissimilarity value. A descriptive and an inferential analysis of the collected variables in between the 
selected clusters was carried out to detect any statistical differences [13]. All the statistical analyses 
were performed with the statistical software STATA®13 (StataCorp, College Station, TX, USA). 
 
Validation cohort 
In order to validate the primary cluster analysis, we recruited an independent population of patients 
with HRCT confirmed bronchiectasis at Ninewells Hospital, Dundee, UK during 2014. We 
hypothesized that the clinical clusters identified in the primary study would show differences in 
neutrophil mediated inflammation. The validation study was conducted as a case control study, with 
a consecutive cohort of 30 patients recruited in each of the 4 identified phenotype arms (identified by 
their primary clustering characteristic), see online supplement. Spontaneous sputum samples were 
obtained and ultracentrifuged at 50,000G for 90mins to obtain supernatant for inflammatory marker 
measurement as previously described [10]. Clinical evaluation was conducted as described above. 
 
 
 
 
RESULTS 
Study population 
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A total of 1,145 patients were enrolled in the five centers (median [IQR] age: 66 [56-74] years; 40% 
males): 286 patients in Dundee, 280 in Galway, 230 in Monza, 190 in Leuven, and 159 in Athens. 
Demographics, clinical, functional and radiological status, microbiology, severity of the disease, and 
long-term antibiotic treatment of the entire study population are presented in Table 1. A detailed 
overview of the five cohorts is reported in Table A in the online supplementary material.  PCA and 
cluster analysis, which are reported in the online supplementary material, allowed the identification 
of four clusters. 
 
Cluster characteristics 
The clinical features of the four clusters are shown in Table 2. 13 patients were allocated in none of 
the four clusters because of missing data and excluded by further analysis. The study population was 
almost equally distributed among the four clusters. Age, sex, body mass index (BMI) and Charlson 
comorbidity index were not significantly different among the four clusters. On the other hand, the 
presence and type of chronic infection were the major key factors defining two of the four clusters.  
Cluster 1 included 16% (n= 179) of the patients and all of them had chronic infection with P. 
aeruginosa. In comparison to all the other clusters, the patients belonging to this cluster presented the 
most severe disease, showing the worse radiological and the highest inflammatory patterns, the lowest 
functional status, the highest number of exacerbations and hospitalizations, and the worse quality of 
life at baseline. Based on these characteristics, Cluster 1 was labelled as “Pseudomonas”. 
There were two intermediate clusters in terms of disease severity (i.e., Cluster 2 and 3), including 
patients with moderate levels of systemic inflammation and functional status, of whom 20% 
experienced at least one hospitalization per year. 
Cluster 2 included 24% (n= 273) of the study population and was characterized by the presence of 
chronic infection with pathogens other than P. aeruginosa. Accordingly, this cluster was labelled as 
“Other chronic infection”. 
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Cluster 3 was the largest cluster, including 33% (n= 373) of the study population. No patients within 
this cluster had chronic infection, but almost all of them had daily sputum and the majority of them 
were smokers or ex-smokers. Accordingly, this cluster was labelled as “Daily sputum”.  
Cluster 4 was composed by 27% (n= 307) of the patients who were the less severe ones, showing the 
lowest level of inflammatory biomarkers, the less severe radiological and functional impairment. 
None of these patients had chronic infection and none had daily sputum. Accordingly, this cluster 
was labelled as “Dry bronchiectasis”. 
The etiology of bronchiectasis was identified in 66% (n= 756) of the patients. Excluding idiopathic 
bronchiectasis, the first three most commonly defined etiologies were post-infective (290, 26%), 
COPD-related (120, 11%), and CTD-related (89, 8%), (Table 1). A detailed distribution of different 
etiologies among the four clusters is depicted in Table 3. No clinically and statistically significant 
differences in terms of bronchiectasis etiology were detected among the four clusters, but for post-
infective and COPD-related bronchiectasis. 
A significant difference in terms of long-term antibiotic treatment, including macrolide and inhaled 
antibiotic, was detected among the four clusters (Table 2). More than 50% of the patients in the 
“Pseudomonas”, one-third of the patients in “Other chronic infection and “Daily sputum” clusters 
were exposed to macrolides. More than one-third of the patients in the “Pseudomonas” cluster were 
on inhaled antibiotic treatment, while few patients received this treatment in the other clusters. 
 
 
 
Quality of life and clinical outcomes during follow up 
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Quality of life was evaluated in 389 (34%) patients, showing a median (IQR) SGRQ value of 
39 (26-58). Significant differences in median values of SGRQ were detected across the four 
clusters with the worse quality of life for patients in the “Pseudomonas” cluster (Table 4). 
Significant differences in terms of both exacerbations and hospitalizations due to 
exacerbations were detected along the four clusters during the one-year follow-up, with the 
higher rates detected in the “Pseudomonas” and “Other chronic infection” clusters. At one-
year follow up no significant differences in mortality were detected among the different 
clusters; however, the “Pseudomonas” cluster showed a significant higher mortality rate 
during the three-year follow up period (Table 4). 
 
Biological and clinical validity of the clusters 
A total of 120 patients were included in a case-control study, using the major characteristics, 
namely the presence of Pseudomonas aeruginosa, chronic colonization with other pathogens, 
daily sputum production without colonization or the absence of these 3 characteristics, see 
Table 5. Patients in “Pseudomonas”, “Other Chronic infection” and “Daily sputum” clusters 
were recruited consecutively. As sputum production was less frequent in the “Dry 
bronchiectasis” cluster, 66 patients were recruited in order to obtain 30 with sputum samples 
available for analysis. Higher levels of neutrophil elastase, myeloperoxidase and interleukin-
1β were found in “Pseudomonas” and “Other chronic infection” clusters, while there were no 
differences in other cytokines, see Figure 1. 
 
 
DISCUSSION 
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The major finding of our study is the evidence of microbiology, including chronic infections with P. 
aeruginosa or other pathogens, and the daily presence of sputum production as the major drivers to 
classify patients with bronchiectasis in four discrete groups. We have further demonstrated that these 
clusters represent clinical phenotypes because they exhibit differences in terms of not only 
inflammatory biomarkers on sputum but also quality of life and long-term clinical outcomes. 
PCA and cluster analysis have been successfully used in recent years to classify patients with asthma 
and COPD in discrete groups according to similar combinations of disease characteristics [14-22]. 
No previous studies have used PCA and cluster analysis to identify clinical phenotypes in 
bronchiectasis. Previous literature defined disease severity through the identification of predictors of 
mortality and hospital admissions using multivariable analysis [6,7]. Although scores such as the BSI 
and the FACED might recognize which patient is globally severe, they do not help physicians in 
identifying which aspect of patient’s management should be addressed firstly in daily clinical practice. 
The present analysis, which does not include the derivation cohort of the BSI paper, sought clusters 
that were not necessarily related to outcomes, but rather patient characteristics providing important 
new information beyond the available scoring systems.  
The presence of chronic infection with Pseudomonas seems to define by itself a specific clinical 
phenotype of patients with bronchiectasis who share a more relevant inflammatory status, a more 
severe disease, worse clinical, functional, and radiological characteristics, and worse quality of life 
and long-term outcomes, in line with previous literature [23]. Two thirds of the patients in the 
Pseudomonas phenotype were on long-term antibiotic treatment, with half of the patients receiving a 
macrolide. From a clinical perspective, it is reasonable to assume that patients belonging to this 
phenotype deserve almost all of the currently available treatment options, including mucus clearance 
techniques, bronchodilators, inhaled or oral long-term antibiotics, long-term oxygen therapy, 
embolization and other measurements to control haemoptysis, and vaccinations to prevent 
 12 
exacerbations. However, this clinical phenotype characterized only 16% of the bronchiectasis patients 
in our cohort, prompting the need to better evaluate characteristics of other phenotypes in order to 
individualize and optimize management.  
Patients with chronic infections other than Pseudomonas recognize a distinct clinical phenotype 
accounting for 24% of the patients with bronchiectasis. A recent study demonstrated worse outcomes 
for patients with a chronic infection due to pathogens other than Pseudomonas compared to patients 
without a chronic infection, but to a lesser extent than those infected with Pseudomonas [6]. Our 
findings related to the Other chronic infection phenotype, showing intermediate rates of 
exacerbations, hospitalizations, and mortality in between the Pseudomonas and the Dry 
bronchiectasis phenotypes, confirming these data. More than one third of the patients in the Other 
chronic infection phenotype received long-term antibiotic treatment, especially macrolide, with only 
5.5% exposed to inhaled antibiotics. There is a paucity of data in literature concerning the evaluation 
of inhaled antibiotics specifically developed for chronic infections with bacteria other than 
Pseudomonas, although the percentage of these patients in the bronchiectasis population is not 
negligible and they do suffer from adverse outcomes.  
The largest clinical phenotype in our cohort, the Daily sputum phenotype, was composed by patients 
who were active smokers, with daily sputum production and without chronic infections. These 
patients had similar level of disease severity and systemic inflammation, with a similar history of 
exacerbations, clinical outcomes and chronic antibiotic use in comparison with patients belonging to 
the Other chronic infection phenotype. These patients would deserve high treatment intensity, 
although the use of long-term antibiotics cannot be guided by microbiological data obtained by 
standard methods. However, it would be conceivable that, although with standard method we were 
not able to identify a chronic infection, new techniques, such as 16S rRNA gene pyrosequencing, 
could allow the microbiological classification of those patients, broadening potential therapeutic 
options [24].  
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Patients in the Dry bronchiectasis phenotype showed the lowest systemic inflammation level, disease 
severity, and clinical impact of bronchiectasis, with the best functional status and without any chronic 
infections. Very few data have been reported in the literature regarding non-clinically significant 
bronchiectasis and certainly further clinical and translational research is needed to identify early 
therapeutic targets in order to prevent disease progression. 
When we validated our findings in an independent cohort of patients with bronchiectasis, we found 
that this classification based on the predominant feature of each cluster (chronic infection with 
Pseudomonas or other bacteria, daily sputum or the absence of daily sputum) is clinically valid with 
clear differences in lung function, symptoms, and disease severity between groups consistent with 
the primary analysis. In addition, we found higher levels of neutrophil elastase, myeloperoxidase and 
interleukin-1β in “Pseudomonas” and “Other chronic infection” clusters, while there were no 
differences in other cytokines. This is very much consistent with previous published data showing 
higher levels of neutrophil inflammatory markers in patients with bacterial colonization and higher 
bacterial loads [10]. This previous literature, together with the present findings, confirms that the 
bacterial colonization status is the most useful clinical parameter to sub-classify patients. 
This study is the first one to apply cluster analysis principles for the identification of clinical 
phenotypes in bronchiectasis. It represents one of the largest cohorts of patients with bronchiectasis 
published so far in literature, including patients from five European countries with a three-year follow-
up. The sample size and the multi-center design increase the inference of our findings. One of the 
strengths of the current analysis is the identification of different phenotypes in bronchiectasis through 
variables that are usually collected during daily clinical practice. Finally, the presence of differences 
in sputum biomarkers and quality of life in a validation cohort strengthens the validity of these 
phenotypes. 
One of the limitations of the present study is that, although we merged multiple cohorts obtained in 
different settings across Europe to ensure representation of different subgroups of patients, all centers 
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were tertiary care ones enrolling a selected population of patients. Further studies should also include 
cohorts of in/outpatients recruited in both secondary and primary care settings and also collect other 
important comorbidities not assessed by the Charlson index, such as depression or anxiety. 
Furthermore, we did not collect the exact date of death and thus we were not able to perform a survival 
analysis on our cohort. 
Cluster analysis, using clinical, microbiological, functional, and radiological variables identified four 
clinical phenotypes easily detected according to the presence of chronic infection with P. aeruginosa 
or other pathogens and daily sputum. Patients belonging to these clinical phenotypes show distinctly 
different patterns of sputum biomarkers, quality of life, and outcomes. Identification of clinical 
phenotypes showing similar biological profiles and prognosis could favour a focused treatment as 
well as test interventions in further randomized controlled trials designed to alter the natural history 
of the disease. 
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FIGURE LEGEND 
Figure 1. Sputum markers of inflammation among different clusters in the validation 
cohort.  
Footnotes. 1: Pseudomonas; 2: Other chronic infection; 3: Daily sputum; 4: Dry 
bronchiectasis. MPO: myeloperoxidase; TNF: tumor necrosis factor 
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Table 1. Patient characteristics of the entire study population 
Variables  
Study cohort n. (%) 1,145 
Demographics and comorbidities 
     Age, years median (IQR) 66 (56-74) 
     Male n. (%) 455 (40) 
     Body Mass Index median (IQR) 25 (22-28) 
     Smokers / Ex-smokers n. (%) 437 (38) 
     Charlson Comorbidities Index>1 n(%) 373 (33) 
Etiology of bronchiectasis 
     Idiopathic n. (%) 373 (34) 
     Post-infective n. (%) 290 (26) 
     COPD n. (%) 120 (11) 
     Connective tissue disease n. (%) 89 (8) 
     Immunodeficiency n. (%) 56 (5) 
     ABPA n. (%) 54 (4.9) 
     Asthma n. (%) 35 (3.2) 
     Inflammatory bowel disease n. (%) 24 (2.2) 
     Ciliary dysfunction n. (%) 20 (1.8) 
     Aspiration n. (%) 14 (1.3) 
     Alpha1-antitrypsin deficiency n. (%) 10 (0.9) 
     Congenital n. (%) 5 (0.5) 
     Other n. (%) 20 (1.8) 
Severity of the disease 
     BSI score median (IQR) 6 (4-11) 
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     FACED score median (IQR) 2 (1-3) 
Radiological Status 
     Reiff score median (IQR) 4 (2-6) 
Clinical status 
     Daily cough n(%) 899 (79) 
     Daily sputum n(%) 744 (65) 
     Prior history of haemoptysis n(%) 206 (18) 
     MRC breathlessness scale median (IQR) 2 (1-3) 
     Long-term oxygen therapy n(%) 86 (7.5) 
     Exacerbations in the previous year median (IQR) 2 (1-3) 
     At least one hospitalization in the previous year n(%) 307 (27) 
Functional Status 
     FEV1, % predicted median (IQR) 75 (55-95) 
Microbiology 
    Chronic infection with at least one pathogen* n. (%) 455 (40) 
          H. influenzae n. (%) 185 (16) 
          P. aeruginosa n. (%) 180 (15) 
          Methicillin-sensitive S. aureus n. (%) 61 (5.3) 
          M. catarrhalis n. (%) 51 (4.5) 
          S. pneumoniae n. (%) 47 (4.1) 
          Enterobacteriaceae n. (%) 29 (2.5) 
          Methicillin-resistant S. aureus n. (%) 21 (1.8) 
          E. coli n. (%) 14 (1.2) 
          K. pneumoniae n. (%) 13 (1.1) 
          Non-tuberculous mycobacteria n. (%) 8 (0.7) 
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          Other n. (%) 31 (2.7) 
Laboratory findings 
     C-reactive protein, mg/L median (IQR) 6 (4-8) 
Long-term antibiotic treatment 
     Either macrolide or inhaled antibiotics n. (%) 388 (34) 
     Macrolide n. (%) 358 (31.3) 
     Inhaled antibiotic treatment n. (%) 90 (7.9) 
     Both macrolide and inhaled antibiotics n. (%) 60 (5.2) 
n: number; IQR: interquartile range 25-75; BSI: Bronchiectasis Severity Index; MRC: medical 
research council; FEV1: forced expiratory volume in the first second. *150 patients had more than 
one pathogen as cause of chronic infection. Among those, 56 patients had P. aeruginosa plus another 
bacteria. 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Baseline characteristics in the four identified clusters 
Variables Cluster 1 Cluster 2 Cluster 3 Cluster 4 
Overall 
p-value 
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  “Pseudomonas” 
“Other chronic 
infection” 
“Daily 
sputum” 
“Dry 
bronchiectasi
s” 
  
Total n. (%) 179 (100) 273 (100) 373 (100) 307 (100)   
Center 
Dundee, UK 44 (25) 128 (47) 90 (24) 24 (68) 
<0.0001 
Leuven, BE 16 (8.9) 19 (7.0) 66 (18) 89 (29) 
Monza, IT 23 (13) 24 (8.8) 87 (23) 96 (31) 
Galway, IR 39 (22) 78 (29) 74 (20) 89 (29) 
Athens, GR 57 (32) 24 (8.8) 56 (15) 9 (2.9) 
Demographics and 
comorbidities 
           
     Age, years median (IQR) 67 (56-75) 65 (56-73) 67 (57-74) 66 (55-74) 0.52 
     Male n.(%) 81 (45) 112 (41) 148 (40) 109 (36) 0.19 
     Body Mass Index median (IQR) 25 (21-27) 25 (22-28) 25 (22-28) 25 (21-28) 0.47 
     Smoker or ex-
smokers 
n.(%) 
56 (31) 90 (33) 165 (44) 121 (39) 0.005 
     Charlson 
Comorbidities Index>1 
n.(%) 
53 (30) 101 (37) 113 (30) 106 (35) 0.20 
Severity of the disease            
     BSI score median (IQR) 14 (11-17) 7 (5-10) 6 (3-9) 5 (3-7) 0.0001 
     FACED score median (IQR) 4 (2-5) 2 (1-3) 2 (0.5-3) 1 (0-3) <0.001 
Radiological status            
     Reiff score median (IQR) 6 (4-9) 4 (2-6) 3 (2-6) 3 (2-6) 0.0001 
Clinical status            
     Daily cough n.(%) 170 (95) 241 (88) 322 (86) 154  (50) <0.0001 
     Daily sputum n.(%) 166 (93) 204 (75) 362 (97) 0 (0) <0.0001 
     Prior history of 
haemoptysis 
n.(%) 
42 (24) 36 (13) 80 (22) 43 (14) 0.002 
     MRC breathlessness 
scale 
median (IQR) 3 (2-5) 2 (1-3) 2 (1-3) 1 (1-2) 0.0001 
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     Long-term oxygen 
therapy 
n.(%) 34 (19) 14 (5.1) 36 (9.7) 0 (0) <0.0001 
     Exacerbations in the 
previous year 
median (IQR) 3 (2-4) 2 (1-3) 2 (1-3) 2 (1-3) 0.0001 
     At least one 
hospitalization in the 
previous year 
n.(%) 109 (61) 63 (23) 90 (24) 36 (12) <0.0001 
Functional Status            
     FEV1 (% predicted) median (IQR) 59 (46-78) 71 (55-93) 77 (57-95) 84 (68-101) 0.0001 
Microbiology            
     Chronic infection 
with P. aeruginosa 
n.(%) 
179 (100) 0 (0) 0 (0) 0 (0) <0.0001 
     Chronic infection 
with other pathogens 
n.(%) 
0 (0) 273 (100) 0 (0) 0 (0) <0.0001 
Laboratory findings            
     C-reactive protein, 
mg/L 
median (IQR) 10.7 (4.0-36.0) 5.0 (3.7-9.0) 
4.5 (2.0-
7.7) 
3.0 (1.2-7.2) 0.0001 
Long-term antibiotic 
treatment 
      
      Either macrolide or 
inhaled antibiotics 
n.(%) 
120 (67) 105 (39) 122 (33) 38 (12) <0.0001 
     Macrolide n.(%) 97 (54) 103 (38) 119 (32) 37 (12) <0.0001 
     Inhaled antibiotics n.(%) 64 (36) 15 (5.5) 7 (1.9) 2 (0.7) <0.0001 
     Both macrolide and 
inhaled 
n.(%) 
41 (23) 13 (4.8) 4 (1.1) 1 (0.3) <0.0001 
n: number; IQR: interquartile range 25-75; BSI: Bronchiectasis Severity Index; MRC: medical 
research council; FEV1: forced expiratory volume in the first second. 
 
 
Table 3. Etiology of bronchiectasis in the four clusters 
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Variables Cluster 1 Cluster 2 Cluster 3 Cluster 4 
Overall p-
value 
  “Pseudomonas” 
“Other chronic 
infection” 
“Daily 
sputum” 
“Dry 
bronchiectasis” 
 
Total n. (%) 179 (100) 273 (100) 373 (100) 307 (100)   
            
Idiopathic 46 (26) 86 (33) 131 (36) 110 (36) 0.09 
Post-infective 63 (36) 54 (21) 96 (26) 77 (25) 0.004 
COPD 21 (12) 29 (11) 50 (14) 20 (6.6) 0.03 
Connective tissue disease 10 (5.6) 26 (9.8) 26 (7.1) 27 (8.9) 0.377 
Immunodeficiency 11 (6.2) 17 (6.4) 14 (3.8) 14 (4.6) 0.436 
ABPA 10 (5.6) 20 (7.6) 12 (3.3) 12 (3.9) 0.083 
Asthma 2 (1.1) 10 (3.8) 8 (2.2) 15 (4.9) 0.071 
Inflammatory bowel 
disease 
3 (1.7) 6 (2.3) 12 (3.3) 3 (1) 0.233 
Ciliary dysfunction 7 (4) 6 (2.3) 5 (1.4) 2 (0.7) 0.055 
Aspiration 2 (1.1) 6 (1.9) 3 (0.8) 3 (1) 0.419 
Alpha1-antitrypsin 
deficiency 
0 (0) 1 (0.4) 3 (0.8) 6 (2) 0.091 
Congenital 0 (0) 2 (0.8) 3 (0.8) 0 (0) 0.284 
Other 2 (1.1) 1 (0.4) 2 (0.5) 15 (4.9) <0.001 
 
 
 
 
 
Table 4. Quality of life and longitudinal outcomes for each identified cluster 
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Variable 
 
Cluster 1 Cluster 2 Cluster 3  Cluster 4 
Overall 
p-value 
  
 
“Pseudomonas” 
“Other chronic 
infection” 
“Daily 
sputum” 
“Dry 
bronchiectasi
s” 
  
Total n. (%)  179 (100) 273 (100) 373 (100) 307 (100)   
Quality of life       
     SGRQ 
median 
(IQR) 
58 (34-72) 43 (27-61) 39 (27-55) 29 (12-40) <0.001 
Outcomes       
     Exacerbations during 
one-year follow-up 
median 
(IQR) 
2 (1-3) 2 (1-2) 1 (0-2) 1 (0-2) 0.0001 
     At least one 
hospitalization during 
one-year follow-up 
n(%) 67 (42) 41 (16) 56 (16) 42 (14) <0.0001 
     Mortality during one-
year follow-up 
n(%) 9 (5.1) 4 (1.5) 13 (3.6) 14 (4.9) 0.12 
     Mortality during 
three-year follow-up 
n(%) 26 (17) 19 (7.6) 24 (8.2) 23 (11) 0.02 
SGRQ: St. George’s Respiratory Questionnaire.  
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Table 5. Patients’ characteristics and quality of life in the validation cohort according 
to the four clusters. 
Variables Cluster 1 Cluster 2 Cluster 3 Cluster 4 
Overall 
p-value 
  “Pseudomonas” 
“Other chronic 
infection” 
“Daily 
sputum” 
“Dry 
bronchiectasi
s” 
  
Demographics and 
comorbidities 
           
     Age, years median (IQR) 70 (62-72) 66 (57-74) 65 (55-72) 63 (55-75) 0.7 
     Male n.(%) 14 (46.6%) 10 (33.3%) 13 (43.3%) 11 (36.7%) 0.7 
     Body Mass Index median (IQR) 24 (21-26) 26 (22-30) 25 (24-30) 26 (22-30) 0.8 
     Smoker or ex-
smokers 
n.(%) 
9 (30%) 8 (27%) 9 (30%) 4 (13.3%) 0.4 
     Charlson 
Comorbidities Index>1 
n.(%) 
11 (37%) 10 (33%) 8 (27%) 12 (40%) 0.7 
Severity of the disease       
     BSI score median (IQR) 12 (9-15) 8 (5-11) 6 (3-9) 6 (4-8) 0.0001 
Radiological status       
     Reiff score median (IQR) 6 (3-10) 3 (2-6) 2 (2-5) 3 (2-4) <0.0001 
Clinical status       
     Daily cough n.(%) 30 (100) 28 (93) 30 (100) 19 (64) <0.0001 
     Daily sputum n.(%) 29 (97) 27 (90) 30 (100) 0 (0) <0.0001 
     Prior history of 
haemoptysis 
n.(%) 
8 (27) 4 (13) 3 (10) 0 (0) 0.02 
     MRC breathlessness 
scale 
median (IQR) 3 (2-5) 3 (2-4) 1 (1-2) 1 (1-2) <0.0001 
     Exacerbations in the 
previous year 
median (IQR) 2 (1-5) 2 (0-2) 1 (0-1) 1 (0-2) <0.0001 
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     At least one 
hospitalization in the 
previous year 
n.(%) 20 (66.7) 15 (50) 5 (16.6) 3 (10.0) <0.0001 
Functional Status       
     FEV1 (% predicted) median (IQR) 51 (35-76) 61 (49-81) 83 (65-97) 93 (59-99) <0.0001 
Microbiology       
     Chronic infection 
with P. aeruginosa 
n.(%) 
30 (100) 0 0  0 <0.0001 
     Chronic infection 
with other pathogens 
n.(%) 
0 30 (100) 0  
0 
<0.0001 
Quality of life       
SGRQ 
 
median (IQR) 58.3 (38.6-70.3) 44.3 (31.8-51.9) 
33.3 (25.6-
37.1) 
36.6 (20-
49.0) 
<0.0001 
Leicester cough 
questionnaire 
median (IQR) 10 (9-16) 13 (10-17) 16 (14-19) 
13.2 (11.0-
19.0) 
0.004 
n: number; IQR: interquartile range 25-75; BSI: Bronchiectasis Severity Index; MRC: medical 
research council; FEV1: forced expiratory volume in the first second; SGRQ: St. George’s 
Respiratory Questionnaire. 
 
